Caveolin-1 gene silencing promotes the activation of PI3K/AKT dependent on Erα36 and the transformation of MCF10ACE

Science China Life Sciences

Volumn 53, Issue 5, 2010, Pages 598-605

  Feng, Shuang ^a   Wang, Yang ^a   Wang, Xi ^a   Wang, Zhao Yi ^c   Cui, Yu Ying ^a   Liu, Jing ^d   Zhao, Chun Hui ^a   Jin, Mei ^a,b   Zou, Wei ^a,b  

^a LIAONING NORMAL UNIVERSITY   (China)

^b Liaoning Key Laboratories of Biotechnology and Molecular Drug Research and Development   (China)

^c CREIGHTON UNIVERSITY   (United States)

^d DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Caveolin 1; Estrogen receptor; PI3K AKT

Indexed keywords

CAVEOLIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; BREAST TUMOR; CELL TRANSFORMATION; DRUG EFFECT; FEMALE; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; DRUG EFFECTS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CAVEOLIN 1; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE SILENCING; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 77953694572     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-010-0100-x     Document Type: Article

References (38)

1. Glass A G, Carreon J D, Hoover R N, et al. Breast cancer incidence, 1980-2006: Combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst, 2007, 99: 1152-1161.
2. Ravdin P M, Cronin K A, Berry D A, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med, 2007, 356: 1670-1674.
3. Gregory A G, Patrice M C, Eric J S, et al. The Class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae. J Biol Chem, 1999, 17: 12043-12048.
4. Hino M, Doihara H, Shimizu N, et al. Caveolin-1 as tumor suppressor gene in breast cancer. Surg Today, 2003, 33: 486-490.
5. Lee S W, Reimer C L, Schnitzer J E, et al. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene, 1998, 16: 1391-1397.
6. Fiucci G, Ravid D, Liscovitch M, et al. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene, 2002, 21: 2365-2375.
7. Sloan E K, Stanley K L, Anderson R L, et al. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene, 2004, 23: 7893-7897.
8. Kong E H, Pike A C, Hubbard R E. Structure and mechanism of the oestrogen receptor. Biochem Soc Trans, 2003, 31(Pt 1): 56-59.
9. Hammes S R, Levin E R. Extranuclear steroid receptors: Nature and actions. Endocr rev, 2007, 28: 726-741.
10. Losel R, Wehing M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol, 2003, 4: 46-56.
11. Marquez D, Chen H W, Pietras R J, et al. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol, 2006, 246: 91-100.
12. Wang Z Y, Zhang X. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun, 2005, 336: 1023-1027.
13. Wang Z Y, Thomas F D, Thomas F D, et al. A variant of estrogen receptor-α, hER-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA, 2005, 103: 9063-9068.
14. Robert C, Minetta C L, Kerrie B B, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor Signaling. Oncogene, 2003, 22: 7316-7339.
15. Michalides R, Griekspoor A, Balkenende A, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. Cancer Cell, 2004, 5: 597-605.
16. Zou W, Mcdaneld L, Smith L M, et al. Caveolin-1 haploinsufficiency leads to partial transformation of human breast epithelial cells. Anticancer Res, 2003, 23: 4581-4586.
17. Duan R, Xie W, Burghardt R C, et al. Estrogen receptor activation of the serum response element in MCF-7 cells through MAPK dependent phosphorylation of Elk-1. Biol Chem, 2001, 276: 11590-11598.
18. Watters J J, Chun T Y, Kim Y N, et al. Estrogen modulation of prolactin gene expression requires an intact mitogenactivated protein kinase signal transduction pathway in cultured rat pituitary cells. Mol Endocrinol, 2000, 14: 1872-1881.
19. Marino M, Acconcia F, Trentalance A, et al. Distinct nongenomic signal transduction pathways controlled by 17beta estradiol regulate DNA synthesis and cyclin D1 gene transcription in HepG2 cells. Mol Biol Cell, 2002, 13: 3720-3729.
20. Altucci L, Addeo R, Cicatiello L, et al. Estrogen induces early and timed activation of cyclin-dependent kinase 4, 5 and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. Endocrinology, 1997, 138: 978-984.
21. Yee D, Lee A V. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia, 2002, 1: 107-115.
22. Anna L K, Erzsebet B, Aniko G, et al. Oestrogen- mediated tyrosine phosphorylation of caveolin-1 and its effect on the oestrogen receptor localization: An in vivo study. Mol Cell Endocrinol, 2005, 245: 128-137.
23. Wayne Z, Lillian M S, Amato G. Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Mol Cell Biol, 2000, 20: 1507-1514.
24. Lee S W, Reimer C L, Schnitzer J E, et al. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene, 1998, 16, 1391-1397.
25. Hurlstone A F, Reid G, Black D M, et al. Analysis of the Caveolin-1 gene at human chromosome 7q31. 1 in primary tumours and tumour-derived cell lines. Oncogene, 1999, 18, 1881-1890.
26. Fiucci G, Ravid D, Reich R, et al. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene, 2002, 21, 2365-2375.
27. Zhang X T, Shen P, Zou W, et al. Caveolin-1 down-regulation activates estrogen receptor alpha expression and leads to 17β-estradiol-stimulated mammary tumorigenesis. Anticancer Res, 2005, 25: 369-375.
28. Razandi M, Pedram A, Ellis R L, et al. ERs associate with and regulate the production of caveolin: Implications for signaling and cellular actions. Mol Endocrinol, 2002, 16: 100-115.
29. Tang S, Wen G B. Membrane initiated estrogen signaling pathway in breast cancer. Int Path Clin Med, 2008, 5: 429-431.
30. Lee Y R, So M C, Jung S H, et al. Upregulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptoralpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochem Biophys Res, 2005, 336: 1221-1226.
31. Sun M, Paciga J E, Cheng J Q, et al. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res, 2001, 61: 5985-5991.
32. Kirkegaard T, Witton C J, Bartlett J M, et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. Pathol, 2005, 207: 139-146.
33. Le L, Xiu Y H, Manijeh P. Tamoxifen and ICI 182, 780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERa. Breast Cancer Res Treat, 2008, 11: 605-621.
34. Ripple M O, Kalmadi S, Eastman A. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival. Breast Cancer Res Treat, 2005, 93: 177-188.
35. Beeram M, Tan Q T, Middleton A, et al. Akt induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol, 2007, 18: 1323-1328.
36. Santen R J, Song R X, Yue W, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. Steroid Biochem Mol Biol, 2002, 80: 239-256.
37. Ripple M O, Kalmadi S, Eastman A. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival. Breast Cancer Res Treat, 2005, 93: 177-188.
38. Song R X, Fan P, Santen R J. Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer. Endocr Relat Cancer, 2006, 13: S3-S13.